Høgdall C K, Høgdall E V, Hørding U, Daugaard S, Clemmensen I, Nørgaard-Pedersen B, Toftager-Larsen K
Department of Obstetrics & Gynecology, Rigshospitalet, University of Copenhagen, Denmark.
Gynecol Oncol. 1991 Nov;43(2):103-7. doi: 10.1016/0090-8258(91)90053-8.
Plasma tetranectin was measured in 67 controls, 121 patients with a benign or malignant ovarian tumor, and 24 patients with another benign gynecologic disease to evaluate the predictive value of plasma tetranectin. A significant reduction of plasma tetranectin was found in every malignant tumor type except for mucinous tumors. Further a significant correlation was found between stage of tumors and plasma tetranectin. Depending on the cutoff level the sensitivity for stage 1 cancer ranged from 52 to 71%. In stage 1 + 2 the sensitivity ranged from 58 to 75% and for advanced cancer (stage 3 + 4) from 80 to 95%. The corresponding specificities ranged from 97 to 84%. Plasma tetranectin may be a useful tool for detecting early stages of ovarian cancer.
对67名对照者、121名患有良性或恶性卵巢肿瘤的患者以及24名患有其他良性妇科疾病的患者进行血浆纤连蛋白四聚体检测，以评估血浆纤连蛋白四聚体的预测价值。除黏液性肿瘤外，在每种恶性肿瘤类型中均发现血浆纤连蛋白四聚体显著降低。此外，还发现肿瘤分期与血浆纤连蛋白四聚体之间存在显著相关性。根据临界值水平，I期癌症的敏感性范围为52%至71%。在I + II期，敏感性范围为58%至75%，晚期癌症（III + IV期）的敏感性范围为80%至95%。相应的特异性范围为97%至84%。血浆纤连蛋白四聚体可能是检测卵巢癌早期阶段的有用工具。
